Get the Stockscreener App
13.85
1.21%
-0.17
Lexeo Therapeutics Inc. stock is currently priced at $13.85, with a 24-hour trading volume of 50,303.
It has seen a -1.21% decreased in the last 24 hours and a +12.97% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $14.33 pivot point. If it approaches the $13.51 support level, significant changes may occur.
Previous Close:
$14.02
Open:
$14.09
24h Volume:
50,303
Market Cap:
$456.29M
Revenue:
-
Net Income/Loss:
$-62.31M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+5.40%
1M Performance:
+12.97%
6M Performance:
+25.68%
1Y Performance:
+0.00%
1D Range:
$13.72
$14.28
52W Range:
$9.32
$22.33
Lexeo Therapeutics Inc. Stock (LXEO) Company Profile
Name
Lexeo Therapeutics Inc.
Sector
Industry
Phone
212-547-9879
Address
345 Park Avenue South, 6th Floor, New York
Lexeo Therapeutics Inc. Stock (LXEO) Latest News
Lexeo Therapeutics (NASDAQ:LXEO) & Repligen (NASDAQ:RGEN) Critical Analysis - Defense World
Defense World
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet - MSN
MSN
Lexeo Therapeutics CEO sells shares worth over $66,000 By Investing.com - Investing.com
Investing.com
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock - Zacks Investment Research
Zacks Investment Research
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock - Yahoo Finance
Yahoo Finance
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
Zacks Investment Research
Lexeo Therapeutics Inc. Stock (LXEO) Financials Data
Lexeo Therapeutics Inc. (LXEO) Net Income 2024
LXEO net income (TTM) was -$62.31 million for the quarter ending December 31, 2023.
Lexeo Therapeutics Inc. (LXEO) Earnings per Share 2024
LXEO earnings per share (TTM) was -$2.4445 for the quarter ending December 31, 2023.
Lexeo Therapeutics Inc. Stock (LXEO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Townsend Richard Nolan | Chief Executive Officer |
May 13 '24 |
Sale |
13.22 |
5,000 |
66,093 |
170,695 |
| Longitude Capital Partners IV, | 10% Owner |
Nov 07 '23 |
Buy |
11.00 |
454,545 |
4,999,995 |
2,567,100 |
| Omega Fund VI, L.P. | 10% Owner |
Nov 07 '23 |
Buy |
11.00 |
454,545 |
4,999,995 |
2,157,623 |
| Lundbeckfond Invest A/S | 10% Owner |
Nov 07 '23 |
Buy |
11.00 |
227,272 |
2,499,992 |
1,835,959 |
About Lexeo Therapeutics Inc.
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
0.77%
1.20%
Cap:
|
Volume (24h):